CD19 and neoplasm: As shown, based on BLI imaging and overall survival assessment (Fig. 5A, B), we find that intraperitoneal administration of MSLN-CAR T cells suppressed tumor growth and resulted in prolonged survival of these mice compared to control mice treated with CD19-CAR T cells (Fig. 5C).